Journal Cover
Nature Medicine
Journal Prestige (SJR): 17.067
Citation Impact (citeScore): 17
Number of Followers: 751  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1078-8956 - ISSN (Online) 1546-170X
Published by NPG Homepage  [144 journals]
  • Author Correction: Thymosin α1 represents a potential potent
           single-molecule-based therapy for cystic fibrosis
    • Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis

      Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis, Published online: 22 June 2018; doi:10.1038/s41591-018-0100-0

      Author Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisAuthor Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis, Published online: 2018-06-22; doi:10.1038/s41591-018-0100-02018-06-22
      DOI: 10.1038/s41591-018-0100-0
       
  • Publisher Correction: Stimulation of entorhinal cortex–dentate gyrus
           circuitry is antidepressive
    • Publisher Correction: Stimulation of entorhinal cortex–dentate gyrus circuitry is antidepressive

      Publisher Correction: Stimulation of entorhinal cortex–dentate gyrus circuitry is antidepressive, Published online: 22 June 2018; doi:10.1038/s41591-018-0084-9

      Publisher Correction: Stimulation of entorhinal cortex–dentate gyrus circuitry is antidepressivePublisher Correction: Stimulation of entorhinal cortex–dentate gyrus circuitry is antidepressive, Published online: 2018-06-22; doi:10.1038/s41591-018-0084-92018-06-22
      DOI: 10.1038/s41591-018-0084-9
       
  • Publisher Correction: Thymosin α1 represents a potential potent
           single-molecule-based therapy for cystic fibrosis
    • Publisher Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis

      Publisher Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis, Published online: 22 June 2018; doi:10.1038/s41591-018-0099-2

      Publisher Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisPublisher Correction: Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis, Published online: 2018-06-22; doi:10.1038/s41591-018-0099-22018-06-22
      DOI: 10.1038/s41591-018-0099-2
       
  • Author Correction: STAT3 labels a subpopulation of reactive astrocytes
           required for brain metastasis
    • Author Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis

      Author Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis, Published online: 19 June 2018; doi:10.1038/s41591-018-0108-5

      Author Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasisAuthor Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis, Published online: 2018-06-19; doi:10.1038/s41591-018-0108-52018-06-19
      DOI: 10.1038/s41591-018-0108-5
       
  • Low-frequency cortical activity is a neuromodulatory target that tracks
           recovery after stroke
    • Low-frequency cortical activity is a neuromodulatory target that tracks recovery after stroke

      Low-frequency cortical activity is a neuromodulatory target that tracks recovery after stroke, Published online: 18 June 2018; doi:10.1038/s41591-018-0058-y

      Recovery of skilled motor function in rodents after stroke correlates with the restoration of low-frequency quasi-oscillatory activity in the motor cortex, and neuromodulatory electrical stimulation targeting this activity can further accelerate recovery.Low-frequency cortical activity is a neuromodulatory target that tracks recovery after stroke, Published online: 2018-06-18; doi:10.1038/s41591-018-0058-y2018-06-18
      DOI: 10.1038/s41591-018-0058-y
       
  • Publisher Correction: Targeting hepatic glutaminase activity to ameliorate
           hyperglycemia
    • Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia

      Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia, Published online: 12 June 2018; doi:10.1038/s41591-018-0047-1

      Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemiaPublisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia, Published online: 2018-06-12; doi:10.1038/s41591-018-0047-12018-06-12
      DOI: 10.1038/s41591-018-0047-1
       
  • p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
    • p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

      p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells, Published online: 11 June 2018; doi:10.1038/s41591-018-0050-6

      CRISPR–Cas9-induced DNA damage triggers p53 to limit the efficiency of gene editing in human pluripotent cells.p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells, Published online: 2018-06-11; doi:10.1038/s41591-018-0050-62018-06-11
      DOI: 10.1038/s41591-018-0050-6
       
  • Suppression of detyrosinated microtubules improves cardiomyocyte function
           in human heart failure
    • Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure

      Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure, Published online: 11 June 2018; doi:10.1038/s41591-018-0046-2

      Post-translational modification of microtubules by detyrosination is prevalent in failing human cardiomyocytes and inhibits cardiomyocyte contraction, suggesting a new therapeutic strategy for improving heart function.Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure, Published online: 2018-06-11; doi:10.1038/s41591-018-0046-22018-06-11
      DOI: 10.1038/s41591-018-0046-2
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.224.83.221
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-